Edwards Lifesciences Accrued rebates decreased by 7.8% to $144.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.4%, from $118.90M to $144.40M. Over 5 years (FY 2020 to FY 2025), Accrued rebates shows an upward trend with a 18.4% CAGR.
other_accrued_rebates| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $74.00M | $82.60M | $77.00M | $78.40M | $89.60M | $91.80M | $116.10M | $112.30M | $130.10M | $139.50M | $131.40M | $120.60M | $120.60M | $140.00M | $139.30M | $118.90M | $143.20M | $158.20M | $156.60M | $144.40M |
| QoQ Change | — | +11.6% | -6.8% | +1.8% | +14.3% | +2.5% | +26.5% | -3.3% | +15.9% | +7.2% | -5.8% | -8.2% | +0.0% | +16.1% | -0.5% | -14.6% | +20.4% | +10.5% | -1.0% | -7.8% |
| YoY Change | — | — | — | — | +21.1% | +11.1% | +50.8% | +43.2% | +45.2% | +52.0% | +13.2% | +7.4% | -7.3% | +0.4% | +6.0% | -1.4% | +18.7% | +13.0% | +12.4% | +21.4% |